Botox: what it is, where it comes from, and how it works

Botox: what it is, where it comes from, and what it is made of

Botox is the brand name for onabotulinumtoxinA, a purified protein derived from botulinum toxin type A produced by the bacterium Clostridium botulinum. When injected in therapeutic doses—measured in nanograms—it temporarily blocks the nerve signal that orders muscle contraction, smoothing expression lines and has dozens of approved medical applications worldwide.

If you have ever wondered where Botox comes from, what the vial your doctor uses actually contains, or how it works inside your body, this guide brings together the answers with the level of detail that normally only appears in pharmacological texts, but in language that any curious patient can follow.

In summary

• Botox comes from botulinum toxin type A, produced by the bacterium Clostridium botulinum, a microorganism that naturally inhabits soil and marine sediments.
• Each vial of Botox contains only ~5 ng of protein complex (900 kDa), human serum albumin, and sodium chloride—an extraordinarily small amount of active protein.
• Its mechanism of action has three steps: the toxin binds to the nerve terminal, is internalized, and cuts the SNAP-25 protein, preventing the release of acetylcholine and therefore muscle contraction.
• There are at least six commercial brands of botulinum toxin (Botox, Dysport, Xeomin, Daxxify, Jeuveau, Myobloc); their units are NOT interchangeable with each other.
• The effect is temporary because nerve terminals regenerate within 3 to 6 months.

---

Where does Botox come from?

Botulinum toxin type A is a protein produced by Clostridium botulinum, a gram-positive, anaerobic, spore-forming bacterium. This microorganism exists naturally in soil, in lake and ocean sediments, and in the intestinal tract of some animals.

C. botulinum produces toxins as part of its metabolism in oxygen-free environments. In nature, these toxins are responsible for botulism, a serious disease known since the 19th century. However, the same biological principle—the ability to selectively relax a muscle—is what science has leveraged to turn it into one of the most versatile therapeutic tools in modern medicine.

The serotypes: from A to G

There are at least seven serotypes of botulinum toxin, classified from A to G. Each serotype cuts a different protein in the SNARE complex, which is the molecular machinery that allows communication between nerve and muscle.

For medicine, only two are relevant:

• Type A — Cuts the SNAP-25 protein. It is the basis of Botox, Dysport, Xeomin, Daxxify, and Jeuveau. It represents the vast majority of clinical and aesthetic applications.
• Type B — Cuts the VAMP/synaptobrevin protein. It is the basis of Myobloc (rimabotulinumtoxinB), used primarily in cervical dystonia.

Serotypes C, D, E, F, and G have relevance in research and veterinary medicine, but are not currently used in human clinical practice.

What does Botox contain? Molecular composition

A vial of Botox (100 units) contains approximately 5 ng of botulinum toxin type A complex, 0.5 mg of human serum albumin, and 0.9 mg of sodium chloride. That is all: three ingredients.

To put that amount in perspective: 5 nanograms equals 0.000000005 grams. It is one of the most potent pharmacological substances in existence, precisely because it acts in infinitesimal quantities.

The structure of the protein complex

Botulinum toxin type A does not exist as an isolated molecule within the Botox vial. It is presented as a 900 kDa complex (kilodaltons), formed by the neurotoxin proper and a group of accessory proteins called hemagglutinins (HA) and a non-toxic non-hemagglutinating protein (NTNH).

Within that complex, the active neurotoxin weighs 150 kDa and is composed of two chains linked by a disulfide bridge:

• Heavy chain (~100 kDa): Functions as a molecular GPS. Its C-terminal end binds to the SV2 receptor on the nerve terminal surface and allows the toxin to enter the cell. Its translocation domain facilitates the passage of the light chain into the interior.
• Light chain (~50 kDa): It is the enzymatic "scissors." Once inside the neuron, it specifically cuts the SNAP-25 protein, one of the three pieces of the SNARE complex necessary to release acetylcholine.

The accessory proteins of the 900 kDa complex have no direct therapeutic function: in nature they protect the neurotoxin from stomach acid during oral intoxication. In the context of an injection, they dissociate at physiological pH and the 150 kDa neurotoxin is free to act.

The excipients: albumin and sodium chloride

Human serum albumin acts as a stabilizer: it prevents toxin molecules from adhering to the walls of the glass vial or aggregating with each other, which would reduce its potency. Sodium chloride (physiological saline) maintains proper osmolarity once the lyophilized powder is reconstituted with saline solution in the clinic.

How Botox is manufactured: from bacteria to vial

Manufacturing begins with cultivation of the Hall strain of Clostridium botulinum in an anaerobic medium containing casein, yeast extract, and glucose. After several days of controlled fermentation, the bacterium secretes the toxin into the culture medium.

The purification process has multiple stages:

1. Acid precipitation — The medium is acidified to precipitate the toxin protein complex.
2. Dissolution and chromatography — The precipitate is redissolved and passes through chromatographic columns that separate the toxin from other bacterial proteins.
3. Crystallization — The 900 kDa complex is obtained in highly pure crystalline form.
4. Formulation — Human serum albumin and sodium chloride are added.
5. Lyophilization — The solution is frozen and water is extracted under vacuum, producing the sterile white powder contained in each vial.
6. Potency and sterility assays — Each batch undergoes rigorous testing before release.

The final product is stored refrigerated (between 2 °C and 8 °C) and maintains its potency for 36 months without opening. In the clinic, the physician reconstitutes the powder with sterile saline solution immediately before application.

This level of control in manufacturing is one of the reasons why botulinum toxin has such a solid safety profile: what reaches your skin is a high-purity pharmaceutical protein, not "the toxin of a bacterium" in wild state.

How Botox works at the molecular level

Botulinum toxin type A blocks the release of acetylcholine at the neuromuscular junction through a three-step process that takes between 24 and 72 hours to complete.

Step 1: Binding

The C-terminal domain of the heavy chain recognizes and binds to the SV2 receptor (Synaptic Vesicle protein 2) located on the motor nerve terminal membrane. This binding is highly specific, which explains why the toxin acts locally at the injection site.

Step 2: Internalization (endocytosis)

Once bound to the receptor, the toxin is engulfed by the cell membrane and enters the neuron within a vesicle (endosome). When the pH inside the endosome drops, the translocation domain of the heavy chain forms a channel that allows the light chain to cross the membrane into the cytoplasm of the neuron.

Step 3: SNAP-25 cleavage (proteolysis)

Now in the cytoplasm, the light chain acts as a zinc endopeptidase: it cleaves nine amino acids from the C-terminal end of the SNAP-25 protein. Without functional SNAP-25, the SNARE complex cannot assemble, acetylcholine vesicles do not fuse with the membrane, and the neurotransmitter is not released. The muscle stops receiving the order to contract.

Why is the effect temporary?

The neuron does not die. Over time, the nerve terminal regenerates new SNAP-25 proteins and forms new functional connections (a process called neural sprouting). This takes between 3 and 6 months, after which muscular movement gradually recovers. For this reason, treatments with botulinum toxin require periodic applications to maintain the result.

Botulinum toxin brands: comparative table

There are six botulinum toxin brands approved by the FDA, each with a different formulation. Their units of potency are NOT equivalent or interchangeable between brands.

Unit equivalence

The units of Botox and Dysport are NOT interchangeable: 1 unit of Botox is equivalent to approximately 2.5–3 units of Dysport. Xeomin units are clinically similar to Botox units (ratio 1:1 in most studies). Myobloc units (type B) are not comparable with any type A brand.

This lack of equivalence is the reason why each brand has a unique generic name (onabotulinumtoxinA, abobotulinumtoxinA, etc.): an FDA requirement since 2009, designed specifically to prevent dosing errors.

How does the doctor choose between Botox and Dysport?

In clinics with access to both products, the selection is usually based on the anatomy of the area to be treated. Dysport has a slightly higher diffusion profile, which can be advantageous in large areas such as the forehead. Botox tends to remain more localized, which is preferable in areas where millimetric precision is required, such as the eye contour or lip. Both have more than 20 years of clinical safety and efficacy data.

History: from botulism to aesthetic medicine

Botulinum toxin went from being a feared poison to becoming one of the most widely used drugs in the world. Here is the journey:

• 1817 — Justinus Kerner, German physician, first describes "sausage poison" (botulus in Latin) and proposes that it could have therapeutic use in controlled doses.
• 1895 — Emile Pierre van Ermengem, Belgian microbiologist, identifies the bacterium Clostridium botulinum following a botulism outbreak in the village of Ellezelles, Belgium.
• 1946 — Edward Schantz successfully isolates botulinum toxin type A in pure crystalline form at the University of Wisconsin.
• 1970s — Ophthalmologist Alan Scott begins injecting botulinum toxin type A into the eye muscles of primates to treat strabismus, as an alternative to surgery.
• 1987 — Ophthalmologist Jean Carruthers, in Vancouver, observes that her patients treated with botulinum toxin for blepharospasm also lose the wrinkles on their forehead. It is the accidental discovery of aesthetic use.
• 1989 — The FDA approves botulinum toxin type A (then called Oculinum, later renamed Botox) for the treatment of strabismus and blepharospasm.
• 1992 — Jean and Alastair Carruthers publish the first scientific study on the use of botulinum toxin for glabellar lines in The Journal of Dermatologic Surgery and Oncology.
• 2002 — The FDA approves Botox Cosmetic for temporary treatment of moderate to severe glabellar lines. It is the first time a drug receives exclusively aesthetic approval.
• 2009 — The FDA requires unique generic names for each botulinum toxin formulation and adds a black box warning about the risk of effect dissemination.
• 2013 — The FDA approves Botox for lateral eye lines (crow's feet).
• 2017 — The FDA approves Botox for forehead lines.

Approved medical and aesthetic uses

Botulinum toxin type A has approved indications that go far beyond facial aesthetics. The major regulatory agencies of the world—FDA (United States), EMA/AEMPS (Europe), COFEPRIS (Mexico), ANVISA (Brazil), INVIMA (Colombia)—have approved its use for various conditions, although the exact list varies by country and brand.

Aesthetic indications

• Glabellar lines (between eyebrows)
• Forehead lines (forehead)
• Lateral canthus lines (crow's feet)
• Other areas treated off-label with broad clinical support: platysmal bands of the neck, perioral lines, gummy smile, chin with "orange peel" appearance, eyebrow elevation (chemical browlift)

Therapeutic indications (selection)

• Blepharospasm
• Strabismus
• Cervical dystonia
• Spasticity of upper and lower limbs
• Chronic migraine (31+ days of headache per month)
• Axillary hyperhidrosis (excessive sweating)
• Overactive bladder
• Chronic sialorrhea (Myobloc)

The regulatory approval of these uses is based on phase III clinical trials and more than 35 years of accumulated pharmacovigilance data since the first approval in 1989.

Safety and regulation

Botulinum toxin type A is one of the most studied injectable drugs in the world, with millions of applications performed annually and a well-documented safety profile over more than three decades of clinical use.

International regulatory framework

• FDA (U.S.): Regulates botulinum toxin as a biological product. Each formulation requires its own approval process (BLA) and has a unique generic name.
• EMA / AEMPS (Europe / Spain): Approves formulations under different brand names (Vistabel instead of Botox Cosmetic, Azzalure instead of aesthetic Dysport, Bocouture instead of aesthetic Xeomin).
• COFEPRIS (Mexico): Requires that all botulinum toxin products have current health registration for commercialization.
• ANVISA (Brazil): Regulates formulations available in the Brazilian market with specific import and storage requirements.
• INVIMA (Colombia): Registers and supervises approved formulations for distribution in Colombia.

What the evidence says about safety

The most common side effects are local and transitory: a slight bruise at the injection site, temporary headache, or rarely, eyelid ptosis (drooping eyelid) when the toxin migrates to an adjacent muscle. These effects resolve spontaneously in days to weeks.

Serious adverse events are extremely rare and have been associated almost exclusively with very high doses used in therapeutic (not aesthetic) indications or with applications performed by untrained personnel.

A key safety factor: botulinum toxin must be applied only by doctors with specific training in facial anatomy and injectable management. The authentic product comes sealed by the manufacturer, is stored under cold chain, and is reconstituted at the time of application.

---

Frequently asked questions

Where does Botox come from?

Botox is obtained from botulinum toxin type A, a protein produced by the bacterium Clostridium botulinum. This bacterium naturally inhabits soil, marine sediments, and the intestinal tract of some animals. In the pharmaceutical process, the Hall strain of C. botulinum is cultured under strict anaerobic conditions, and the toxin that the bacterium secretes is purified through acid precipitation and chromatography until obtaining a very high purity protein complex. What arrives in the vial is a pharmaceutical protein, not a bacterium or living organism.

What does Botox contain?

A 100-unit Botox vial contains three ingredients: approximately 5 nanograms of botulinum toxin type A complex (a 900 kDa protein), 0.5 mg of human serum albumin as a stabilizer, and 0.9 mg of sodium chloride. The amount of active protein is extraordinarily small—5 nanograms equal five billionths of a gram. The product comes as a lyophilized powder (vacuum-dried) that the doctor reconstitutes with sterile saline solution just before injecting it.

What is Botox made of?

The active ingredient of Botox is onabotulinumtoxinA, a purified 150 kDa neurotoxin contained within a 900 kDa protein complex. The neurotoxin is composed of a heavy chain (~100 kDa) that directs the molecule to the nerve terminal and a light chain (~50 kDa) that acts as an enzyme cutting the SNAP-25 protein. The complex also includes accessory proteins (hemagglutinins) that have no therapeutic function. The excipients are human serum albumin and sodium chloride, both components widely used in pharmaceutical products.

What are the components of Botox?

The components of Botox are three: the botulinum toxin type A complex (the 150 kDa neurotoxin plus accessory proteins, forming a 900 kDa complex), human serum albumin, and sodium chloride. Human serum albumin acts as a stabilizer, preventing toxin molecules from adhering to the glass vial walls or aggregating with each other, which would reduce its clinical potency. Sodium chloride ensures proper physiological osmolarity when the lyophilized powder is reconstituted with sterile saline solution. It does not contain preservatives, antibiotics, collagen, hyaluronic acid, or any other additives.

Where does botulinum toxin come from?

Botulinum toxin is a protein naturally produced by various strains of the bacterium Clostridium botulinum during their anaerobic metabolism (without oxygen). In nature, this bacterium is found in soils all over the world, in aquatic sediments, and in the intestines of certain animals. There are seven serotypes (A-G), but only types A and B are used in medicine. For pharmaceutical manufacturing, the specific Hall strain of C. botulinum is cultured in controlled laboratory conditions and the secreted toxin undergoes a rigorous purification process.

Where do they get facial Botox from?

The Botox used in facial treatments is exactly the same product used in all indications: it is obtained by culturing the bacterium Clostridium botulinum (Hall strain) in the laboratory and purifying the toxin it produces. There is no different "facial" version of the product. What changes is the dose and injection technique that the doctor adapts according to the area of the face: between the eyebrows, forehead, eye contour, or other areas. The pharmaceutical formulation is identical, approved by the FDA and other international regulatory agencies.

How does Botox work?

Botox works by blocking the release of acetylcholine at the neuromuscular junction through a three-step process. First, the heavy chain of the toxin binds to the SV2 receptor at the nerve terminal. Second, the toxin is internalized within the neuron by endocytosis. Third, the light chain cuts the SNAP-25 protein, preventing the SNARE complex from assembling the acetylcholine vesicles with the membrane. Without acetylcholine, the muscle does not receive the signal to contract. The effect is temporary because the neuron regenerates new SNAP-25 proteins within 3 to 6 months.

What is facial Botox?

The term "facial Botox" refers to the application of botulinum toxin type A in the facial muscles for aesthetic purposes. The product used is Botox (onabotulinumtoxinA) or another brand of botulinum toxin type A. It is injected into specific muscles—corrugator, procerus, orbicularis oculi, frontalis—to relax the contractions that cause dynamic wrinkles such as frown lines, crow's feet, and forehead lines. It is not a substance different from therapeutic Botox; the difference lies in the indication, dose, and injection points.

What does Botox contain?

Botox contains only three components: botulinum toxin type A complex (~5 ng), human serum albumin (0.5 mg), and sodium chloride (0.9 mg). It does not contain collagen, hyaluronic acid, or any type of filler—it is a neuromodulator, not a filling material. Before application, the doctor reconstitutes the lyophilized powder with sterile saline solution. The formulation is intentionally simple: fewer excipients means fewer possibilities of allergic reactions or interference with the activity of the toxin.

Is Botox the same as Dysport?

No. Botox (onabotulinumtoxinA) and Dysport (abobotulinumtoxinA) are two different formulations of botulinum toxin type A, manufactured by different laboratories (Allergan and Galderma, respectively) with different purification processes. The most practical difference is that their units are not equivalent: 1 unit of Botox is equivalent to approximately 2.5–3 units of Dysport. Additionally, the Dysport protein complex (~500 kDa) is smaller than Botox (900 kDa), which gives it a slightly different diffusion profile. Both products have FDA approval and decades of clinical evidence.

Where is botulinum toxin extracted from?

Botulinum toxin is extracted from the culture medium of the bacterium Clostridium botulinum. It is not extracted directly from the bacterium itself, but from the solution where it grows: during fermentation, C. botulinum secretes the toxin into the surrounding medium. That medium is subjected to a process of acid precipitation, chromatography, and crystallization to obtain the protein in pure state. It is then formulated with stabilizing excipients and lyophilized. The result is a sterile pharmaceutical powder, far removed from the original bacterium.

What is the composition of Botox?

The composition of Botox includes the 900 kDa botulinum toxin type A complex (which in turn contains the 150 kDa neurotoxin along with accessory hemagglutinating proteins), human serum albumin as a stabilizer, and sodium chloride as an isotonic agent. The 150 kDa neurotoxin is the active molecule, composed of a heavy chain and a light chain linked by a disulfide bridge. The heavy chain directs the toxin to the motor nerve; the light chain cuts the SNAP-25 protein inside the neuron. It is an intentionally minimalist formulation designed to maximize the stability and purity of the active ingredient.